Drug Trial Radar · NCT05266586
Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe as an Adjunct to HIS Therapy
Last checked: Nov 19, 2026Latest source record: Jul 3, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
119
Actual
Start
Mar 9, 2022
Primary completion
Aug 12, 2022
Study completion Sep 8, 2022
Sponsor
- Lead sponsor
- NewAmsterdam PharmaIndustry
- Sponsor type
- Industry
- First posted
- Mar 4, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will be a placebo-controlled, double-blind, randomized, phase 2 study to evaluate the efficacy, safety, and tolerability of obicetrapib 10 mg, both in combination with ezetimibe 10 mg and as monotherapy, as an adjunct to high-intensity statin therapy.
Conditions
- Dyslipidemias
- High Cholesterol
- Hypercholesterolemia
Interventions
ObicetrapibDrug
tablets
Ezetimibe 10mgDrug
capsules; 10 mg ezetimibe tablets filled into capsule shells, 1 tablet per capsule.
Obicetrapib placeboOther
tablets; no active ingredient
Ezetimibe placeboOther
capsules; no active ingredient
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) for Combination Treatment Group Compared With the Placebo Group [Friedewald]Time frame: 12-weeks
- Median Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) for Combination Treatment Group Compared With the Placebo Group [Friedewald]Time frame: 12-Weeks
- LS Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) for Combination Treatment Group Compared With the Placebo Group [Friedewald]Time frame: 12-Weeks
- Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) for Combination Treatment Group Compared With the Placebo Group [PUC]Time frame: 12-Weeks
- Median Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) for Combination Treatment Group Compared With the Placebo Group [PUC]Time frame: 12-Weeks
- LS Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) for Combination Treatment Group Compared With the Placebo Group [PUC]Time frame: 12-Weeks
Locations
16 sites in 1 country. Site status is shown where the registry gives one.
Velocity Clinical Research - Westlake d.b.a National Research Institute
Los Angeles, California
Valley Clinical Trials, Inc.
Northridge, California
Ocala Cardiovascular Research
Ocala, Florida
A & R Research Group, LLC
Pembroke Pines, Florida
Progressive Medical Research
Port Orange, Florida
Meridian Clinical Research - Savannah, GA
Savannah, Georgia
Velocity Clinical Research
Meridian, Idaho
Biofortis, Inc
Addison, Illinois
Northwest Heart Clinical Research, LLC
Arlington Heights, Illinois
Midwest Institute for Clinical Research
Indianapolis, Indiana
Research Integrity LLC
Owensboro, Kentucky
Oakland Medical Research Center
Troy, Michigan
Mercury Street Medical
Butte, Montana
Meridian Clinical Research- Springdale, OH
Cincinnati, Ohio
Aventiv Research, Inc.
Columbus, Ohio
Summit Research Group, LLC
Munroe Falls, Ohio
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.